FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 315 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer MOST POPULAR Study Says Exercise Combats Side Effects of Chemo and Other Meds... July 7, 2021 EMA Recommends Granting a Marketing Authorisation for Fedratinib December 23, 2020 T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... July 9, 2020 FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Load more HOT NEWS Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy... Heartburn Medications Pulled From Shelves Because They May Cause Cancer
